Cadherin switching in ovarian cancer progression
Tóm tắt
The roles of the cadherins in the progression of ovarian cancer to the late stages of the disease state when malignant cells have disseminated within the peritoneal cavity remain poorly understood. In view of these observations, we have undertaken a comprehensive survey of the cadherin subtypes present in normal ovarian surface epithelium and peritoneum and in the tumors and peritoneal effusions of women diagnosed with Stage I or Stage II primary ovarian cancer using a degenerate cloning strategy for sequences highly conserved among this family of cell adhesion molecules. On the basis of the nucleotide sequences of the resultant PCR products, multiple cadherin subtypes (E‐, N‐, P‐cadherin, and cadherin‐4, ‐6, and ‐11) were found to be present in these normal and malignant tissues and cells. P‐cadherin was determined to be the predominant cadherin subtype in normal peritoneum, peritoneal effusions and Stage II tumor masses. An increase in P‐cadherin mRNA and protein expression levels in ovarian tumor masses with progression to later stages of the disease state was confirmed by Northern and Western blot analysis, respectively. In addition, we have determined that the cadherin‐associated protein, known as β‐catenin, is expressed in normal peritoneum, ovarian tumors and malignant cell effusions obtained from women with Stage I or Stage II cancer. Immunoprecipitation studies demonstrated that P‐cadherin was capable of interacting with β‐catenin in these normal and malignant tissues and cells. Collectively, these findings suggest that the regulated expression of P‐cadherin/β‐catenin complexes in ovarian tumor cells may represent a key step in disease progression. © 2003 Wiley‐Liss, Inc.
Từ khóa
Tài liệu tham khảo
Cannistra SA, 1993, Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H, Cancer Res, 53, 3830
Tomita K, 2000, Cadherin switching in human prostate cancer progression, Cancer Res, 60, 3650
Auersperg N, 1998, The biology of ovarian cancer, Semin Oncol, 25, 281
Suzuki S, 1990, Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue, Cell Regul, 2, 261, 10.1091/mbc.2.4.261
Pishvaian MJ, 1999, Cadherin‐11 is expressed in invasive breast cancer cell lines, Cancer Res, 59, 947
Hines MD, Inhibition of cadherin function differentially affects markers of terminal differentiation in cultured human keratinocytes, J Cell Sci, 112, 4569, 10.1242/jcs.112.24.4569
Hirai Y, 1989, Expression and role of E‐ and P‐cadherin adhesion molecules in embryonic histogenesis. 1 Skin morphogenesis, Development, 105, 271, 10.1242/dev.105.2.271
Sellar GC, 2001, BARX2 induces cadherin‐6 expression and is a functional suppressor of ovarian cancer progression, Cancer Res, 61, 6977
Shimazui T, 1996, Complex cadherin expression in renal cell carcinoma, Cancer Res, 56, 3234
Bailey T, 1998, Altered cadherin and catenin complexes in the Barret's esophagus–dysplasia–adenocarcinoma sequence: correlation with disease progression and dedifferentiation, Am J Pathol, 152, 135
Haq A, 2001, Abnormal P‐cadherin and altered expression of β‐catenin in ulcerative colitis associated dysplasia and colorectal cancer, Dis Colon Rectum, 44, A2
Fujioka T, 2001, Expression of E‐cadherin and beta‐catenin in primary and peritoneal metastatic ovarian carcinoma, Oncol Rep, 8, 249